Data Characteristics
siRNA nucleic acid drug pharmacovigilance data comes from various sources. These include clinical trial reports, real-world evidence (RWE) data, post-market surveillance reports, scientific literature (e.g., PubMed, Scopus), and regulatory agency databases (e.g., FDA Adverse Event Reporting System, FAERS). Update frequencies vary. Clinical trial data is typically released periodically as studies progress. RWE data may update quarterly or semi-annually. Regulatory databases usually update continuously in real-time.
Document structures also vary. Reports often use structured or semi-structured formats. These formats contain fields such as patient information, medication history, adverse event descriptions (MedDRA coding), severity, and outcomes. Scientific literature primarily consists of unstructured text. Specific adverse reactions to siRNA nucleic acid drugs, such as off-target effects, immunogenicity reactions, and delivery system-related adverse reactions (e.g., hepatotoxicity, infusion reactions), appear frequently in text descriptions. These descriptions may involve specific biomarker test results. These are unique data fields and units.
Constraints on Knowledge Base Retrieval and Recall
The diverse data sources and update frequencies for siRNA nucleic acid drugs require a knowledge base that can effectively integrate structured and unstructured data. It must also support incremental update mechanisms. The frequent occurrence of specialized terminology, off-target effects, and immunogenicity in unstructured text places higher demands on text chunking granularity and semantic understanding. Adverse event severity and outcomes are critical information. Knowledge base retrieval must accurately identify and recall document chunks containing these core judgment fields.
siRNA nucleic acid drug delivery systems are strongly associated with adverse reactions. This involves specific biomarker test results. The knowledge base needs robust support for named entity recognition (NER) and entity relationship extraction. This ensures retrieval accuracy and avoids interference from irrelevant information. These characteristics collectively necessitate fine-tuning of context length, chunking strategies, and similarity calculation methods during retrieval and recall.
Configuration Settings
| Configuration Item | Recommended Value | Rationale The knowledge base configuration values are common starting points. They should be evaluated against the reader's own samples.
| Configuration Item | Recommended Value | Rationale |
|---|---|---|
Chunk Size | 500-800 characters | Balances completeness of adverse event descriptions with density of specialized content like off-target effects. |
Chunk Overlap | 100-150 characters | Ensures semantic continuity across chunks, especially for disease progression descriptions. |
Recall Count | Top 5-8 chunks | Balances retrieval efficiency and coverage, avoiding excessive recall of irrelevant documents. |
Similarity Threshold | 0.75-0.85 | Ensures recalled content is highly relevant to the query intent, filtering noise. |
Rerank Return Count | 3-5 chunks | Selects the most relevant results to improve the accuracy of the final output. |
maxContext | 4000-6000 tokens | Accommodates the context requirements of complex adverse event reports. |
Common Pitfalls
- Empty or irrelevant search results: This often happens when specific adverse reactions to siRNAs (e.g., off-target effects, immunogenicity) are not effectively tokenized and entity-recognized. This prevents relevant documents from being correctly indexed.
- Recalled document chunks lack critical information: This can occur if the
Chunk Sizeis too small. This separates the adverse event description from critical judgment fields such as severity and outcome. - Long query times or high resource consumption: This usually happens when
Recall CountormaxContextare set too high. This leads to processing too many candidate documents or too much context for complex queries.
Validation Steps
- Query for combinations of typical adverse reactions (e.g., hepatotoxicity, thrombocytopenia) and specific siRNA nucleic acid drugs. Check if the recalled results include key clinical symptoms, laboratory indicators, and treatment measures.
- Verify the presence of specific fields like MedDRA codes, severity ratings, and biomarker test values in the recalled document chunks. Ensure their semantic completeness.
- Simulate high-concurrency queries. Monitor system response time and resource utilization to ensure they remain within acceptable limits.
- Test queries containing
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.